The DOI matches its Crossref record; 100 of the 100 references it cites were found in a registry or an index.
Multiple Endocrine Neoplasia Type 2 and Familial Medullary Thyroid Carcinoma: An Update
Open accessAbstract
CONTEXT: Over the last decade, our knowledge of the multiple endocrine neoplasia (MEN) type 2 syndromes MEN2A and MEN2B and familial medullary thyroid carcinoma (FMTC) has expanded greatly. In this manuscript, we summarize how recent discoveries have enhanced our understanding of the molecular basis of these diseases and led to improvements in the diagnosis and management of affected patients. EVIDENCE ACQUISITION: We reviewed the English literature through PubMed from 2000 to the present, using the search terms medullary thyroid carcinoma, multiple endocrine neoplasia type 2, familial medullary thyroid carcinoma, RET proto-oncogene, and calcitonin. EVIDENCE SYNTHESIS: Over 70 RET mutations are known to cause MEN2A, MEN2B, or FMTC, and recent findings from studies of large kindreds with these syndromes have clouded the relationship between genotype and phenotype, primarily because of the varied clinical presentation of different families with the same RET mutation. This clinical variability has also confounded decisions about the timing of prophylactic thyroidectomy for MTC, the dominant endocrinopathy associated with these syndromes. A distinct advance has been the demonstration through phase II and phase III clinical trials that molecular targeted therapeutics are effective in the treatment of patients with locally advanced or metastatic MTC. CONCLUSIONS: The effective management of patients with MEN2A, MEN2A, and FMTC depends on an understanding of the variable behavior of disease expression in patients with a specific RET mutation. Information gained from molecular testing, biochemical analysis, and clinical evaluation is important in providing effective management of patients with either early or advanced-stage MTC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Haugen, B. R., Alexander, E. K., Bible, K. C., Doherty, G. M., Mandel, S. J., Nikiforov, Y. E., Pacini, F., Randolph, G. W., Sawka, A. M., Schlumberger, M., et al. (2016) · Thyroid® · doi:10.1089/thy.2015.0020 · Cited by 16,535
Self-citationGefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M. W. N., Silver, R. T., Goldman, J. M., Stone, R. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062867 · Cited by 3,488
CONSENSUS: Guidelines for Diagnosis and Therapy of MEN Type 1 and Type 2
Brandi, M. L. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.12.5658 · Cited by 2,031
Cooper, D. S., Doherty, G. M., Haugen, B. R., Kloos, R. T., Lee, S. L., Mandel, S. J., Mazzaferri, E. L., McIver, B., Sherman, S. I., & Tuttle, R. M. (2006) · Thyroid · doi:10.1089/thy.2006.16.109 · Cited by 2,016
Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A
Mulligan, L. M., Kwok, J. B. J., Healey, C. S., Elsdon, M. J., Eng, C., Gardner, E., Love, D. R., Mole, S. E., Moore, J. K., Papi, L., et al. (1993) · Nature · doi:10.1038/363458a0 · Cited by 1,966
Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret
Schuchardt, A., D'Agati, V., Larsson-Blomberg, L., Costantini, F., & Pachnis, V. (1994) · Nature · doi:10.1038/367380a0 · Cited by 1,614
Wells, S. A., Robinson, B. G., Gagel, R. F., Dralle, H., Fagin, J. A., Santoro, M., Baudin, E., Elisei, R., Jarzab, B., Vasselli, J. R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.5040 · Cited by 1,559
Self-citationMedullary Thyroid Cancer: Management Guidelines of the American Thyroid Association
Kloos (Chair), R. T., Eng, C., Evans, D. B., Francis, G. L., Gagel, R. F., Gharib, H., Moley, J. F., Pacini, F., Ringel, M. D., Schlumberger, M., et al. (2009) · Thyroid · doi:10.1089/thy.2008.0403 · Cited by 1,357
Self-citationMutations in the RET proto-oncogene are associated with MEN 2A and FMTC
Donis-Keller, H., Dou, S., Chi, D., Carlson, K. M., Toshima, K., Lairmore, T. C., Howe, J. R., Moley, J. F., Goodfellow, P., & Wells, S. A. (1993) · Human Molecular Genetics · doi:10.1093/hmg/2.7.851 · Cited by 1,303
Self-citationHirschsprung disease, associated syndromes and genetics: a review
Amiel, J., Sproat-Emison, E., Garcia-Barcelo, M., Lantieri, F., Burzynski, G., Borrego, S., Pelet, A., Arnold, S., Miao, X., Griseri, P., et al. (2008) · Journal of Medical Genetics · doi:10.1136/jmg.2007.053959 · Cited by 1,206
Hofstra, R. M. W., Landsvater, R. M., Ceccherini, I., Stulp, R. P., Stelwagen, T., Luo, Y., Pasini, B., Hoppener, J. W. M., van Amstel, H. K. P., Romeo, G., et al. (1994) · Nature · doi:10.1038/367375a0 · Cited by 1,149
Catalytic specificity of protein-tyrosine kinases is critical for selective signalling
Songyang, Z., Carraway, K. L., Eck, M. J., Harrison, S. C., Feldman, R. A., Mohammadi, M., Schlessinger, J., Hubbard, S. R., Smith, D. P., Eng, C., et al. (1995) · Nature · doi:10.1038/373536a0 · Cited by 919
Activation of RET as a Dominant Transforming Gene by Germline Mutations of MEN2A and MEN2B
Santoro, M., Carlomagno, F., Romano, A., Bottaro, D. P., Dathan, N. A., Grieco, M., Fusco, A., Vecchio, G., Matoskova, B., Kraus, M. H., et al. (1995) · Science · doi:10.1126/science.7824936 · Cited by 841
Self-citationKIF5B-RET fusions in lung adenocarcinoma
Kohno, T., Ichikawa, H., Totoki, Y., Yasuda, K., Hiramoto, M., Nammo, T., Sakamoto, H., Tsuta, K., Furuta, K., Shimada, Y., et al. (2012) · Nature Medicine · doi:10.1038/nm.2644 · Cited by 834
Romeo, G., Ronchetto, P., Luo, Y., Barone, V., Seri, M., Ceccherini, I., Pasini, B., Bocciardi, R., Lerone, M., Kääriäinen, H., et al. (1994) · Nature · doi:10.1038/367377a0 · Cited by 700
Cohen, E. E. W., Rosen, L. S., Vokes, E. E., Kies, M. S., Forastiere, A. A., Worden, F. P., Kane, M. A., Sherman, E., Kim, S., Bycott, P., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.9566 · Cited by 623
Carlson, K. M., Dou, S., Chi, D., Scavarda, N., Toshima, K., Jackson, C. E., Wells, S. A., Goodfellow, P. J., & Donis-Keller, H. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.4.1579 · Cited by 600
Self-citationChen, H., Sippel, R. S., O'Dorisio, M. S., Vinik, A. I., Lloyd, R. V., & Pacak, K. (2010) · Pancreas · doi:10.1097/mpa.0b013e3181ebb4f0 · Cited by 593
Modigliani, E., Cohen, R., Campos, J., Conte‐Devolx, B., Maes, B., Boneu, A., Schlumberger, M., Bigorgne, J., Dumontier, P., Leclerc, L., et al. (1998) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1998.00392.x · Cited by 570
Kurzrock, R., Sherman, S. I., Ball, D. W., Forastiere, A. A., Cohen, R. B., Mehra, R., Pfister, D. G., Cohen, E. E. W., Janisch, L., Nauling, F., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.4145 · Cited by 550
Roman, S., Lin, R., & Sosa, J. A. (2006) · Cancer · doi:10.1002/cncr.22244 · Cited by 548
Early Malignant Progression of Hereditary Medullary Thyroid Cancer
Machens, A., Niccoli-Sire, P., Hoegel, J., Frank-Raue, K., van Vroonhoven, T. J., Roeher, H.-D., Wahl, R. A., Lamesch, P., Raue, F., Conte-Devolx, B., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa012915 · Cited by 545
Elisei, R., Bottici, V., Luchetti, F., Di Coscio, G., Romei, C., Grasso, L., Miccoli, P., Iacconi, P., Basolo, F., Pinchera, A., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030550 · Cited by 537
Self-citationWells, S. A., Gosnell, J. E., Gagel, R. F., Moley, J., Pfister, D., Sosa, J. A., Skinner, M., Krebs, A., Vasselli, J., & Schlumberger, M. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.6604 · Cited by 519
Self-citationBarbet, J., Campion, L., Kraeber-Bodéré, F., & Chatal, J.-F. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0044 · Cited by 407
Prophylactic Thyroidectomy in Multiple Endocrine Neoplasia Type 2A
Skinner, M. A., Moley, J. A., Dilley, W. G., Owzar, K., DeBenedetti, M. K., & Wells, S. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043999 · Cited by 381
Self-citationPhase II Clinical Trial of Sorafenib in Metastatic Medullary Thyroid Cancer
Lam, E. T., Ringel, M. D., Kloos, R. T., Prior, T. W., Knopp, M. V., Liang, J., Sammet, S., Hall, N. C., Wakely, P. E., Vasko, V. V., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.0068 · Cited by 377
Costante, G., Meringolo, D., Durante, C., Bianchi, D., Nocera, M., Tumino, S., Crocetti, U., Attard, M., Maranghi, M., Torlontano, M., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1590 · Cited by 372
RET as a Diagnostic and Therapeutic Target in Sporadic and Hereditary Endocrine Tumors
de Groot, J. W. B., Links, T. P., Plukker, J. T. M., Lips, C. J. M., & Hofstra, R. M. W. (2006) · Endocrine Reviews · doi:10.1210/er.2006-0017 · Cited by 356
Schlumberger, M. J., Elisei, R., Bastholt, L., Wirth, L. J., Martins, R. G., Locati, L. D., Jarzab, B., Pacini, F., Daumerie, C., Droz, J.-P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.7815 · Cited by 340
Self-citationMechanism of Activation of the ret Proto-oncogene by Multiple Endocrine Neoplasia 2A Mutations
Asai, N., Iwashita, T., Matsuyama, M., & Takahashi, M. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.3.1613 · Cited by 340
Laparoscopic adrenalectomy compared to open adrenalectomy for benign adrenal neoplasms.
Lm, B., Doherty, G. M., Norton, J. A., Nj, S., Ma, Q., & Moley, J. F. (1996) · PubMed · Cited by 336
Current Approaches and Recommended Algorithm for the Diagnostic Localization of Pheochromocytoma
Ilias, I., & Pacak, K. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031091 · Cited by 332
Structure and Chemical Inhibition of the RET Tyrosine Kinase Domain
Knowles, P. P., Murray-Rust, J., Kjær, S., Scott, R. P., Hanrahan, S., Santoro, M., Ibáñez, C. F., & McDonald, N. Q. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605604200 · Cited by 302
Self-citationEisenhofer, G., Lenders, J. W., Timmers, H., Mannelli, M., Grebe, S. K., Hofbauer, L. C., Bornstein, S. R., Tiebel, O., Adams, K., Bratslavsky, G., et al. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2010.153320 · Cited by 290
Prospects of Remission in Medullary Thyroid Carcinoma According to Basal Calcitonin Level
Machens, A., Schneyer, U., Holzhausen, H.-J., & Dralle, H. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1836 · Cited by 290
Robinson, B. G., Paz-Ares, L., Krebs, A., Vasselli, J., & Haddad, R. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2461 · Cited by 257
Self-citationAgrawal, N., Jiao, Y., Sausen, M., Leary, R., Bettegowda, C., Roberts, N. J., Bhan, S., Ho, A. S., Khan, Z., Bishop, J., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2703 · Cited by 255
Self-citationHigh Prevalence of RAS Mutations in RET -Negative Sporadic Medullary Thyroid Carcinomas
Moura, M. M., Cavaco, B. M., Pinto, A. E., & Leite, V. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1921 · Cited by 244
Chatal, J.-F., Campion, L., Kraeber-Bodéré, F., Bardet, S., Vuillez, J.-P., Charbonnel, B., Rohmer, V., Chang, C.-H., Sharkey, R. M., Goldenberg, D. M., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.4917 · Cited by 232
Parent-of-origin effects in multiple endocrine neoplasia type 2B.
Carlson, K. M., Bracamontes, J. R., Jackson, C. E., Clark, R., Lacroix, A., Wells, S. A., & Goodfellow, P. J. (1994) · PubMed Central · Cited by 229
Self-citationBerndt, I., Reuter, M., Saller, B., Frank-Raue, K., Groth, P., Grußendorf, M., Raue, F., Ritter, M. M., & Höppner, W. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.3.4619 · Cited by 229
Provocative Agents and the Diagnosis of Medullary Carcinoma of the Thyroid Gland
WELLS, S. A., BAYLIN, S. B., LINEHAN, W. M., FARRELL, R. E., COX, E. B., & COOPER, C. W. (1978) · Annals of Surgery · doi:10.1097/00000658-197808000-00002 · Cited by 220
Self-citationManagement of Pheochromocytomas in Patients with Multiple Endocrine Neoplasia Type 2 Syndromes
Lairmore, T. C., Ball, D. W., Baylin, S. B., & Wells, S. A. (1993) · Annals of Surgery · doi:10.1097/00000658-199306000-00001 · Cited by 218
Self-citationBolk, S., Pelet, A., Hofstra, R. M. W., Angrist, M., Salomon, R., Croaker, D., Buys, C. H. C. M., Lyonnet, S., & Chakravarti, A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.1.268 · Cited by 214
Dottorini, M. E., Assi, A., Sironi, M., Sangalli, G., Spreafico, G., & Colombo, L. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960415)77:8<1556::aid-cncr20>3.0.co;2-y · Cited by 211
RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture
Santoro, M., Melillo, R. M., & Fusco, A. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02289 · Cited by 190
Self-citationA Phase II Trial of Imatinib Therapy for Metastatic Medullary Thyroid Carcinoma
de Groot, J. W. B., Zonnenberg, B. A., van Ufford-Mannesse, P. Q., de Vries, M. M., Links, T. P., Lips, C. J. M., & Voest, E. E. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0649 · Cited by 180
Evidence of a Low Prevalence of RAS Mutations in a Large Medullary Thyroid Cancer Series
Ciampi, R., Mian, C., Fugazzola, L., Cosci, B., Romei, C., Barollo, S., Cirello, V., Bottici, V., Marconcini, G., Rosa, P. M., et al. (2013) · Thyroid · doi:10.1089/thy.2012.0207 · Cited by 178
Eng, C., Mulligan, L. M., Smith, D. P., Healey, C. S., Frilling, A., Raue, F., Neumann, H. P. H., Ponder, M. A., & Ponder, B. A. J. (1995) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1995.tb01903.x · Cited by 173
Targeting the RET Pathway in Thyroid Cancer
Wells, S. A., & Santoro, M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2742 · Cited by 168
Self-citationNiitani, H. (1995) · PubMed · Cited by 167
(GETC), A. T. G. D. D. T. A. C., Schlumberger, M., Abdelmoumene, N., Delisle, M., & Couette, J. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.73 · Cited by 167
Busnardo, B., Girelli, M. E., Simioni, N., Nacamulli, D., & Busetto, E. (1984) · Cancer · doi:10.1002/1097-0142(19840115)53:2<278::aid-cncr2820530216>3.0.co;2-z · Cited by 159
Miyauchi, A., Futami, H., Hai, N., Yokozawa, T., Kuma, K., Aoki, N., Kosugi, S., Sugano, K., & Yamaguchi, K. (1999) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1999.tb00658.x · Cited by 158
Woyach, J. A., Kloos, R. T., Ringel, M. D., Arbogast, D., Collamore, M., Zwiebel, J. A., Grever, M. R., Villalona-Calero, M. A., & Shah, M. H. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1631 · Cited by 156
Hypercalcitoninemia is not pathognomonic of medullary thyroid carcinoma
Toledo, S. P., Lourenço, D. M., Santos, M. A., Tavares, M. R., Toledo, R. A., & de Menezes Correia-Deur, J. E. (2009) · Clinics · doi:10.1590/s1807-59322009000700015 · Cited by 154 · cited 1×
“The so-called secondary CCH, occurring in association with diseases such as hyperparathyroidism, hypergastrinemia, and renal insufficiency, or after the administration of certain drugs, is not a premalignant condition (28).”
BackgroundFrank‐Raue, K., Rybicki, L. A., Erlic, Z., Schweizer, H., Winter, A., Milos, I., Toledo, S. P. A., Toledo, R. A., Tavares, M. R., Alevizaki, M. K., et al. (2010) · Human Mutation · doi:10.1002/humu.21385 · Cited by 150
Sex-Related C Cell Hyperplasia in the Normal Human Thyroid: A Quantitative Autopsy Study
Guyétant, S., Rousselet, M., Durigon, M., Chappard, D., Franc, B., Guerin, O., & Saint‐André, J. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.1.3684 · Cited by 144
Frank‐Raue, K., Höppner, W., Frilling, A., Kotzerke, J., Dralle, H., Haase, R., Mann, K., Seif, F., Kirchner, R., Rendl, J., et al. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.81.5.1780 · Cited by 141
RET activation by germline MEN2A and MEN2B mutations.
Borrello, M. G., Smith, D. P., Pasini, B., Bongarzone, I., Greco, A., Lorenzo, M. J., Arighi, E., Miranda, C., Eng, C., & Alberti, L. (1995) · PubMed · Cited by 134
Asari, R., Scheuba, C., Kaczirek, K., & Niederle, B. (2006) · Archives of Surgery · doi:10.1001/archsurg.141.12.1199 · Cited by 125
Miyauchi, A., Onishi, T., Morimoto, S., Takai, S., Matsuzuka, F., Kuma, K., Maeda, M., & Kumahara, Y. (1984) · Annals of Surgery · doi:10.1097/00000658-198404000-00014 · Cited by 118
Schuffenecker, I., Ginet, N., Goldgar, D., Eng, C., Chambe, B., Boneu, A., Houdent, C., Pallo, D., Schlumberger, M. J., Thivolet, C. H., et al. (1997) · Europe PMC (PubMed Central) · Cited by 117
Karges, W., Dralle, H., Raue, F., Mann, K., Reiners, C., Grußendorf, M., Hüfner, M., Niederle, B., & Brabant, G. E. (2004) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-2004-815727 · Cited by 115
Eisenhofer, G., Tischler, A. S., & de Krijger, R. R. (2011) · Endocrine Pathology · doi:10.1007/s12022-011-9188-1 · Cited by 112
Immunotherapy for Medullary Thyroid Carcinoma by Dendritic Cell Vaccination
Schott, M., Seißler, J., Lettmann, M., Fouxon, V., Scherbaum, W. A., & Feldkamp, J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.10.7949 · Cited by 112
Gastrointestinal Manifestations of Multiple Endocrine Neoplasia Type 2
Cohen, M. S., Phay, J. E., Albinson, C. H., DeBenedetti, M. K., Skinner, M. A., Lairmore, T. C., Doherty, G. M., Balfe, D. M., Wells, S. A., & Moley, J. F. (2002) · Annals of Surgery · doi:10.1097/00000658-200205000-00006 · Cited by 110
Self-citationMenko, F. H., van der Luijt, R. B., de Valk, I. A. J., Toorians, A. W. F. T., Sepers, J. M., van Diest, P. J., & Lips, C. J. M. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.1.8136 · Cited by 110
Hong, D. S., Cabanillas, M. E., Wheler, J. J., Naing, A., Tsimberidou, A. M., Ye, L., Waguespack, S. G., Hernández, M., Naggar, A. K. E., Bidyasar, S., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1899 · Cited by 109
Ballerini, P. F., Struski, S., Cresson, C., Prade, N., Toujani, S., Deswarte, C., Dobbelstein, S., Petit, A., Lapillonne, H., Gautier, E., et al. (2012) · Leukemia · doi:10.1038/leu.2012.109 · Cited by 107
Pheochromocytoma penetrance varies by RET mutation in MEN 2A
Quayle, F. J., Fialkowski, E., Benveniste, R. J., & Moley, J. F. (2007) · Surgery · doi:10.1016/j.surg.2007.09.013 · Cited by 103
Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma
Frank‐Raue, K., Fabel, M., Delorme, S., Haberkorn, U., & Raue, F. (2007) · European Journal of Endocrinology · doi:10.1530/eje-06-0695 · Cited by 100
Leboeuf, R., Langlois, M., Martin, M., Ahnadi, C. E., & Fink, G. D. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1429 · Cited by 96
Failure to Recognize Multiple Endocrine Neoplasia 2B: More Common Than We Think?
Wray, C. J., Rich, T. A., Waguespack, S. G., Lee, J. E., Perrier, N. D., & Evans, D. B. (2007) · Annals of Surgical Oncology · doi:10.1245/s10434-007-9665-4 · Cited by 96
Schöffski, P., Elisei, R., Müller, S. P., Brose, M. S., Shah, M. H., Licitra, L. F., Jarząb, B., Медведев, В. С., Kreissl, M. C., Niederle, B., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.5508 · Cited by 92
Reference Intervals for Serum Calcitonin in Men, Women, and Children
Basuyau, J.-P., Mallet, E., Leroy, M., & Brunelle, P. (2004) · Clinical Chemistry · doi:10.1373/clinchem.2003.026963 · Cited by 91
Jasim, S., Ying, A. K., Waguespack, S. G., Rich, T. A., Grubbs, E. G., Jiménez, C., Hu, M. I.-N., Cote, G. J., & Habra, M. A. (2010) · Thyroid · doi:10.1089/thy.2010.0328 · Cited by 85
RET receptor signaling: Dysfunction in thyroid cancer and Hirschsprung's disease
Asai, N., Jijiwa, M., Enomoto, A., Kawai, K., Maeda, K., Ichiahara, M., Murakumo, Y., & Takahashi, M. (2006) · Pathology International · doi:10.1111/j.1440-1827.2006.01942.x · Cited by 79
The many faces of RET dysfunction in kidney
Jain, S. R. (2009) · Organogenesis · doi:10.4161/org.5.4.10048 · Cited by 75
Ain, K. B., Lee, C., & Williams, K. D. (2007) · Thyroid · doi:10.1089/thy.2006.0289 · Cited by 74
Marsh, D. J., McDowall, D., Hyland, V. J., Andrew, S. D., Schnitzler, M., Gaskin, E., Nevell, D. F., DIAMOND, T. H., Delbridge, L., Clifton-Bligh, P. B., et al. (1996) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1996.505292.x · Cited by 74
Self-citationOncological implications of RET gene mutations in Hirschsprung’s disease
Sijmons, R. H., Hofstra, R. M. W., Wijburg, F. A., et al. (1998) · Gut · doi:10.1136/gut.43.4.542 · Cited by 66
Selective arterial chemoembolization for hepatic metastases from medullary thyroid carcinoma
Lorenz, K., Brauckhoff, M., Behrmann, C., Sekulla, C., Ukkat, J., Brauckhoff, K., Gimm, O., & Dralle, H. (2005) · Surgery · doi:10.1016/j.surg.2005.09.020 · Cited by 65
Dendritic Cell Vaccination in Medullary Thyroid Carcinoma
Stift, A., Sachet, M., Yagubian, R., Bittermann, C., Dubsky, P. C., Brostjan, C., Pfragner, R., Niederle, B., Jakesz, R., Gnant, M., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0698 · Cited by 64
Phase II Study of Celecoxib in Metastatic Differentiated Thyroid Carcinoma
Mrózek, E., Kloos, R. T., Ringel, M. D., Kresty, L. A., Snider, P., Arbogast, D., Kies, M. S., Munden, R. F., Busaidy, N. L., Klein, M. J., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2498 · Cited by 54
de Graaf, R. P. F. D. J. S. (1999) · The European Journal of Surgery · doi:10.1080/11024159950189320 · Cited by 43
Diarrhoea and thyroid carcinoma.
Williams, E. D. (1966) · PubMed · Cited by 43
Peppa, Μ., Boutati, E. I., Kamakari, S., et al. (2008) · European Journal of Endocrinology · doi:10.1530/eje-08-0476 · Cited by 41
Scholten, A., Valk, G. D., Ulfman, D., Rinkes, I. H. M. B., & Vriens, M. R. (2011) · Annals of Surgery · doi:10.1097/sla.0b013e318237480c · Cited by 41
Laparoscopic adrenalectomy: Balancing the operative indications with the technical advances
Mazzaglia, P. J., & Vezeridis, M. P. (2010) · Journal of Surgical Oncology · doi:10.1002/jso.21565 · Cited by 31
Normal Range of Calcitonin in Children Measured by a Chemiluminescent Two-Site Immunometric Assay
Verga, U., Morpurgo, P. S., Vaghi, I., Radetti, G., & Beck‐Peccoz, P. (2006) · Hormone Research in Paediatrics · doi:10.1159/000092848 · Cited by 27
Management Strategies for Aggressive Cushing's Syndrome: From Macroadenomas to Ectopics
Pozza, C., Graziadio, C., Giannetta, E., Lenzi, A., & Isidori, A. M. (2012) · Journal of Oncology · doi:10.1155/2012/685213 · Cited by 24
Occurrence of Pheochromocytoma in a MEN2A Family with Codon 609 Mutation of the RET Protooncogene
Igaz, P., Patócs, A., Rácz, K., Klein, I., Váradi, A., & Ésik, O. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.6.8623 · Cited by 24
When Is Prophylactic Thyroidectomy Indicated for Patients with the RET Codon 609 Mutation?
Calva, D., O’Dorisio, T. M., O'Dorisio, M. S., Lal, G., Sugg, S. L., Weigel, R. J., & Howe, J. R. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0524-3 · Cited by 19
Hernández, C., Simó, R., Oriola, J., & Mesa, J. (1997) · Thyroid · doi:10.1089/thy.1997.7.51 · Cited by 12
Medullary Thyroid Carcinoma: Ethical Issues for the Surgeon
Shuman, A. G., Shaha, A. R., Tuttle, R. M., Fins, J. J., & Morris, L. G. T. (2012) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2235-4 · Cited by 11
Cited by
Guidelines for the management of thyroid cancer
Perros, P., Boelaert, K., Colley, S., Evans, C., Evans, R. M., Gerrard BA, G., Gilbert, J., Harrison, B., Johnson, S. J., Giles, T. E., et al. (2014) · Clinical Endocrinology · doi:10.1111/cen.12515 · Cited by 1,372
Biologic and Clinical Perspectives on Thyroid Cancer
Fagin, J. A., & Wells, S. A. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1501993 · Cited by 990
Self-citationBoucai, L., Zafereo, M., & Cabanillas, M. E. (2024) · JAMA · doi:10.1001/jama.2023.26348 · Cited by 701
Realizing the promise of cancer predisposition genes
Rahman, N. (2014) · Nature · doi:10.1038/nature12981 · Cited by 624
Hampel, H., Bennett, R. L., Buchanan, A., Pearlman, R., & Wiesner, G. L. (2015) · Genetics in Medicine · doi:10.1038/gim.2014.147 · Cited by 587
Metadata
- Authors
- Wells, S. A., Pacini, F., Robinson, B. G., & Santoro, M.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2013-08
- Volume
- 98
- Issue
- 8
- Pages
- 3149-3164
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2101005605
- Cited by
- 338
- References
- 100
- FWCI
- 24.06
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.